Glycated Albumin (GA) is More Advantageous than Hemoglobin A1c for Evaluating the Efficacy of Sitagliptin in Achieving Glycemic Control in Patients with Type 2 Diabetes
スポンサーリンク
概要
- 論文の詳細を見る
Objective The aim of this study was to compare the utility of hemoglobin A1c (HbA1c) and glycated albumin (GA) for evaluating the efficacy of the dipeptidyl peptidase-4 (DPP-4) inhibitor, sitagliptin, in patients with type 2 diabetes. Methods Sitagliptin (50 mg) was administered orally once daily in 67 outpatients with type 2 diabetes. Drug effectiveness was deemed present if the HbA1c or GA level decreased by 5% at week 4 and week 12 relative to the baseline value. Results The mean HbA1c level decreased from 8.1±1.0% at baseline to 7.8±0.9% at week 4 and 7.2±0.8% at week 12. The mean GA level decreased from 25.0±4.5% at baseline to 22.2±3.8% at week 4 and 20.8±3.5% at week 12. At week 4 and week 12, the drug was effective in 37.8% and 71.6% of the patients, respectively, when assessed based on changes in HbA1c, and in 83.6% and 97.0% of the patients, respectively, when assessed based on changes in GA. Conclusion GA is superior to HbA1c for evaluating the efficacy of sitagliptin treatment in patients with type 2 diabetes.
- 一般社団法人 日本内科学会の論文
一般社団法人 日本内科学会 | 論文
- A Patient with Diffuse Cutaneous Systemic Sclerosis Complicated by Antineutrophil-cytoplasmic Antibody-associated Vasculitis Exhibiting Honeycomb Lung without Volume Loss
- Parkinson's Disease and the Cardio-ankle Vascular Stiffness Index
- Pseudohypoparathyroidism Type II in a Woman with a History of Thyroid Surgery
- A Novel Frameshift Mutation in Exon 4 Causing a Deficiency of High-molecular-weight Kininogen in a Patient with Splenic Infarction
- Risk Factors for Liver Injury with an Elevated Serum Bilirubin Concentration Caused by Antituberculous Drugs